Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pierre Wijermans

Showing results (11-20 of 26) with videos related to

Pageof 3
Sort By:
Blood|January 11, 2007
Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom?Jan J Cornelissen, Wim L J van Putten, Leo F Verdonck, et al.
Haematologica|May 25, 2010
Value of allogeneic versus autologous stem cell transplantation and chemotherapy in patients with myelodysplastic syndromes and secondary acute myeloid leukemia. Final results of a prospective randomized European Intergroup TrialTheo de Witte, Anne Hagemeijer, Stefan Suciu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 6, 2006
Cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients age 60 years or older with previously untreated acute myeloid leukemiaFrancis Giles, David Rizzieri, Judith Karp, et al.
Blood|January 14, 2011
Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patientsFrancesca Gay, Alessandra Larocca, Pierre Wijermans, et al.
Haematologica|August 10, 2012
Safety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trialsAntonio Palumbo, Anders Waage, Cyrille Hulin, et al.
Nederlands Tijdschrift Voor Geneeskunde|October 28, 2010
[Autologous stem cell transplantation in haematological disorders,1980-2002]Mariëlle M J Beckers, Leo F Verdonck, Jan J Cornelissen, et al.
Blood|November 3, 2009
A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myelomaHenk M Lokhorst, Bronno van der Holt, Sonja Zweegman, et al.
Blood|January 25, 2012
IMWG consensus on maintenance therapy in multiple myelomaHeinz Ludwig, Brian G M Durie, Philip McCarthy, et al.
Genes, Chromosomes & Cancer|February 26, 2017
Genomic array as compared to karyotyping in myelodysplastic syndromes in a prospective clinical trialMarian J Stevens-Kroef, Daniel Olde Weghuis, Najat ElIdrissi-Zaynoun, et al.
Haematologica|March 1, 2013
Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trialsSara Bringhen, Maria Victoria Mateos, Sonja Zweegman, et al.
Pageof 3

Showing results (11-20 of 26) with videos related to

Sort By:
Pageof 3
Blood|January 11, 2007
Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom?Jan J Cornelissen, Wim L J van Putten, Leo F Verdonck, et al.
Haematologica|May 25, 2010
Value of allogeneic versus autologous stem cell transplantation and chemotherapy in patients with myelodysplastic syndromes and secondary acute myeloid leukemia. Final results of a prospective randomized European Intergroup TrialTheo de Witte, Anne Hagemeijer, Stefan Suciu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 6, 2006
Cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients age 60 years or older with previously untreated acute myeloid leukemiaFrancis Giles, David Rizzieri, Judith Karp, et al.
Blood|January 14, 2011
Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patientsFrancesca Gay, Alessandra Larocca, Pierre Wijermans, et al.
Haematologica|August 10, 2012
Safety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trialsAntonio Palumbo, Anders Waage, Cyrille Hulin, et al.
Nederlands Tijdschrift Voor Geneeskunde|October 28, 2010
[Autologous stem cell transplantation in haematological disorders,1980-2002]Mariëlle M J Beckers, Leo F Verdonck, Jan J Cornelissen, et al.
Blood|November 3, 2009
A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myelomaHenk M Lokhorst, Bronno van der Holt, Sonja Zweegman, et al.
Blood|January 25, 2012
IMWG consensus on maintenance therapy in multiple myelomaHeinz Ludwig, Brian G M Durie, Philip McCarthy, et al.
Genes, Chromosomes & Cancer|February 26, 2017
Genomic array as compared to karyotyping in myelodysplastic syndromes in a prospective clinical trialMarian J Stevens-Kroef, Daniel Olde Weghuis, Najat ElIdrissi-Zaynoun, et al.
Haematologica|March 1, 2013
Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trialsSara Bringhen, Maria Victoria Mateos, Sonja Zweegman, et al.
Pageof 3